The  ||| S:0 E:4 ||| DT
future  ||| S:4 E:11 ||| NN
is  ||| S:11 E:14 ||| VBZ
predetermined  ||| S:14 E:28 ||| VBN
in  ||| S:28 E:31 ||| IN
severe  ||| S:31 E:38 ||| JJ
sepsis ||| S:38 E:44 ||| NN
,  ||| S:44 E:46 ||| ,
so  ||| S:46 E:49 ||| RB
what  ||| S:49 E:54 ||| WP
are  ||| S:54 E:58 ||| VBP
the  ||| S:58 E:62 ||| DT
implications ||| S:62 E:74 ||| NNS
?  ||| S:74 E:76 ||| .
A  ||| S:76 E:78 ||| DT
high  ||| S:78 E:83 ||| JJ
rate  ||| S:83 E:88 ||| NN
of  ||| S:88 E:91 ||| IN
death  ||| S:91 E:97 ||| NN
from  ||| S:97 E:102 ||| IN
septic  ||| S:102 E:109 ||| JJ
shock  ||| S:109 E:115 ||| NN
persists  ||| S:115 E:124 ||| VBZ
despite  ||| S:124 E:132 ||| IN
general  ||| S:132 E:140 ||| JJ
improvements  ||| S:140 E:153 ||| NNS
in  ||| S:153 E:156 ||| IN
care ||| S:156 E:160 ||| NN
.  ||| S:160 E:162 ||| .
The  ||| S:162 E:166 ||| DT
relative  ||| S:166 E:175 ||| JJ
failure  ||| S:175 E:183 ||| NN
of  ||| S:183 E:186 ||| IN
mechanistically  ||| S:186 E:202 ||| VBG
based  ||| S:202 E:208 ||| VBN
therapies  ||| S:208 E:218 ||| NNS
in  ||| S:218 E:221 ||| IN
various  ||| S:221 E:229 ||| JJ
clinical  ||| S:229 E:238 ||| JJ
trials  ||| S:238 E:245 ||| NNS
should  ||| S:245 E:252 ||| MD
also  ||| S:252 E:257 ||| RB
trigger  ||| S:257 E:265 ||| VB
a  ||| S:265 E:267 ||| DT
reconsideration  ||| S:267 E:283 ||| NN
of  ||| S:283 E:286 ||| IN
such  ||| S:286 E:291 ||| JJ
mechanistic  ||| S:291 E:303 ||| JJ
approaches ||| S:303 E:313 ||| NNS
.  ||| S:313 E:315 ||| .
Despite  ||| S:315 E:323 ||| IN
reversion  ||| S:323 E:333 ||| NN
of  ||| S:333 E:336 ||| IN
shock  ||| S:336 E:342 ||| NN
by  ||| S:342 E:345 ||| IN
hydrocortisone ||| S:345 E:359 ||| NN
,  ||| S:359 E:361 ||| ,
the  ||| S:361 E:365 ||| DT
similar  ||| S:365 E:373 ||| JJ
death  ||| S:373 E:379 ||| NN
rate  ||| S:379 E:384 ||| NN
compared  ||| S:384 E:393 ||| VBN
with  ||| S:393 E:398 ||| IN
nonsteroid-treated  ||| S:398 E:417 ||| JJ
patients  ||| S:417 E:426 ||| NNS
suggests  ||| S:426 E:435 ||| VBZ
that  ||| S:435 E:440 ||| IN
factors  ||| S:440 E:448 ||| NNS
other  ||| S:448 E:454 ||| JJ
than  ||| S:454 E:459 ||| IN
shock  ||| S:459 E:465 ||| NN
itself  ||| S:465 E:472 ||| PRP
are  ||| S:472 E:476 ||| VBP
responsible  ||| S:476 E:488 ||| JJ
for  ||| S:488 E:492 ||| IN
death ||| S:492 E:497 ||| NN
.  ||| S:497 E:499 ||| .
This  ||| S:499 E:504 ||| DT
may  ||| S:504 E:508 ||| MD
be  ||| S:508 E:511 ||| VB
predetermined  ||| S:511 E:525 ||| VBN
and  ||| S:525 E:529 ||| CC
relate  ||| S:529 E:536 ||| VBP
to  ||| S:536 E:539 ||| TO
gene  ||| S:539 E:544 ||| NN
variants ||| S:544 E:552 ||| NN
,  ||| S:552 E:554 ||| ,
the  ||| S:554 E:558 ||| DT
functionality  ||| S:558 E:572 ||| NN
of  ||| S:572 E:575 ||| IN
gene  ||| S:575 E:580 ||| NN
expression ||| S:580 E:590 ||| NN
,  ||| S:590 E:592 ||| ,
age ||| S:592 E:595 ||| NN
,  ||| S:595 E:597 ||| ,
an  ||| S:597 E:600 ||| DT
association  ||| S:600 E:612 ||| NN
with  ||| S:612 E:617 ||| IN
chronic  ||| S:617 E:625 ||| JJ
diseases  ||| S:625 E:634 ||| NNS
such  ||| S:634 E:639 ||| JJ
as  ||| S:639 E:642 ||| IN
diabetes  ||| S:642 E:651 ||| NN
and  ||| S:651 E:655 ||| CC
cancer ||| S:655 E:661 ||| NN
,  ||| S:661 E:663 ||| ,
or  ||| S:663 E:666 ||| CC
perhaps  ||| S:666 E:674 ||| RB
the  ||| S:674 E:678 ||| DT
treatments  ||| S:678 E:689 ||| NNS
being  ||| S:689 E:695 ||| VBG
given  ||| S:695 E:701 ||| VBN
for  ||| S:701 E:705 ||| IN
these  ||| S:705 E:711 ||| DT
diseases ||| S:711 E:719 ||| NNS
.  ||| S:719 E:721 ||| .
These  ||| S:721 E:727 ||| DT
aspects  ||| S:727 E:735 ||| NNS
are  ||| S:735 E:739 ||| VBP
discussed  ||| S:739 E:749 ||| VBN
in  ||| S:749 E:752 ||| IN
this  ||| S:752 E:757 ||| DT
review  ||| S:757 E:764 ||| NN
in  ||| S:764 E:767 ||| IN
the  ||| S:767 E:771 ||| DT
light  ||| S:771 E:777 ||| NN
of  ||| S:777 E:780 ||| IN
arguments  ||| S:780 E:790 ||| NNS
that  ||| S:790 E:795 ||| WDT
support  ||| S:795 E:803 ||| VBP
a  ||| S:803 E:805 ||| DT
hypothesis  ||| S:805 E:816 ||| NN
of  ||| S:816 E:819 ||| IN
outcome  ||| S:819 E:827 ||| NN
predetermination ||| S:827 E:843 ||| NN
.  ||| S:843 E:845 ||| .
Not  ||| S:845 E:849 ||| RB
only  ||| S:849 E:854 ||| RB
constitutive  ||| S:854 E:867 ||| JJ
factors ||| S:867 E:874 ||| NNS
,  ||| S:874 E:876 ||| ,
but  ||| S:876 E:880 ||| CC
also  ||| S:880 E:885 ||| RB
acute  ||| S:885 E:891 ||| JJ
and  ||| S:891 E:895 ||| CC
chronic  ||| S:895 E:903 ||| JJ
environmental  ||| S:903 E:917 ||| JJ
factors  ||| S:917 E:925 ||| NNS
may  ||| S:925 E:929 ||| MD
be  ||| S:929 E:932 ||| VB
responsible ||| S:932 E:943 ||| JJ
.  ||| S:943 E:945 ||| .
An  ||| S:945 E:948 ||| DT
important  ||| S:948 E:958 ||| JJ
consequence  ||| S:958 E:970 ||| NN
would  ||| S:970 E:976 ||| MD
be  ||| S:976 E:979 ||| VB
the  ||| S:979 E:983 ||| DT
ability  ||| S:983 E:991 ||| NN
to  ||| S:991 E:994 ||| TO
perform  ||| S:994 E:1002 ||| VB
early  ||| S:1002 E:1008 ||| JJ
prognostication  ||| S:1008 E:1024 ||| NN
in  ||| S:1024 E:1027 ||| IN
an  ||| S:1027 E:1030 ||| DT
individual  ||| S:1030 E:1041 ||| JJ
patient  ||| S:1041 E:1049 ||| NN
using  ||| S:1049 E:1055 ||| VBG
biomarkers ||| S:1055 E:1065 ||| NNS
.  ||| S:1065 E:1067 ||| .
On  ||| S:1067 E:1070 ||| IN
this  ||| S:1070 E:1075 ||| DT
basis ||| S:1075 E:1080 ||| NN
,  ||| S:1080 E:1082 ||| ,
new  ||| S:1082 E:1086 ||| JJ
therapies  ||| S:1086 E:1096 ||| NNS
could  ||| S:1096 E:1102 ||| MD
be  ||| S:1102 E:1105 ||| VB
tested  ||| S:1105 E:1112 ||| VBN
to  ||| S:1112 E:1115 ||| TO
reduce  ||| S:1115 E:1122 ||| VB
mortality  ||| S:1122 E:1132 ||| NN
rates  ||| S:1132 E:1138 ||| NNS
with  ||| S:1138 E:1143 ||| IN
the  ||| S:1143 E:1147 ||| DT
response  ||| S:1147 E:1156 ||| NN
and  ||| S:1156 E:1160 ||| CC
toxicity  ||| S:1160 E:1169 ||| NN
of  ||| S:1169 E:1172 ||| IN
these  ||| S:1172 E:1178 ||| DT
therapies  ||| S:1178 E:1188 ||| NNS
being  ||| S:1188 E:1194 ||| VBG
predefined  ||| S:1194 E:1205 ||| NNS
using  ||| S:1205 E:1211 ||| VBG
pharmacogenetic  ||| S:1211 E:1227 ||| JJ
testing ||| S:1227 E:1234 ||| NN
.  ||| S:1234 E:1236 ||| .
